De Diego Lorenzo A, Kashoob M, Romero M, Parera A, Durán F, Piqueras B, Santos L, Cos E, Clemente G
Servicio de Aparato Digestivo (Sección Hepatología), Hospital General U, Gregorio Marañón, Madrid.
Rev Esp Enferm Dig. 1997 May;89(5):399-401.
The case of a patient ulcerative colitis involving an autoimmune base who was treated with recombinant alpha-2b interferon for presenting chronic active hepatitis in relation to virus C is reported. Such treatment was achieved in addition to improving the hepatic disease normalizing the transaminases control the outbreak of ulcerative colitis that the patient was presenting from some days before beginning the treatment. Various aspects are discussed related to the autoimmunity in the ulcerative colitis and in the chronic C hepatitis and the exarcebation of autoimmune phenomena which may lead to interferon therapeutic. As a basis for the above and the review of the literature, we concluded that the existence of ulcerative colitis does not contraindicate the use of alpha-2b interferon in patient with chronic hepatitis, although special control of the disease should be carried out during the treatment period.
报告了一例患有自身免疫性基础的溃疡性结肠炎患者,因丙型肝炎出现慢性活动性肝炎而接受重组α-2b干扰素治疗的病例。除改善肝脏疾病使转氨酶正常化外,这种治疗还控制了患者在开始治疗前几天就出现的溃疡性结肠炎发作。讨论了与溃疡性结肠炎和慢性丙型肝炎中的自身免疫以及可能导致干扰素治疗的自身免疫现象加重相关的各个方面。基于上述情况及文献综述,我们得出结论,溃疡性结肠炎的存在并不 contraindicate 在慢性肝炎患者中使用α-2b干扰素,尽管在治疗期间应特别对该疾病进行监测。 (注:“contraindicate”未准确翻译,可能是原文有误,正常应为“禁忌”之类的意思)